Buprenorphine Use and the Risk of Dental Adverse Events in Patients With Opioid Use Disorder.

ABSTRACT:

Background

The US Food and Drug Administration (FDA) issued a drug safety communication warning of dental-related adverse events (DAE) reported in patients using buprenorphine films or tablets in January 2022. This study utilized more recent data with a broader dental outcome definition beyond what has been previously reported to provide comprehensive evidence of this risk.

Objective

Assess the association between buprenorphine use and the risk of DAE among opioid use disorder (OUD) patients.

Design

A retrospective cohort study.

Methods

Using the Veradigm-MarketScan® linked dataset, adults aged ⩾18 years with an OUD diagnosis between June 30, 2018, and July 1, 2023, and who met our selection criteria were included. Patients were grouped as: (1) BUP users and (2

SUBMITTER: Okeke CM 

PROVIDER: S-EPMC12852581 | biostudies-literature | 2026 Jan-Dec

REPOSITORIES: biostudies-literature